Announcement of Sales Launch for "Neurophet AQUA,"
an MR Device Workstation Program to Assist
in the Diagnosis of Neurodegenerative Diseases

December 19, 2022


Clairvo Technologies Co., Ltd. (Headquarters: Chiyoda, Tokyo; CEO: Riichi Yamada, hereafter "Clairvo") has entered into an exclusive business alliance contract with NEUROPHET Inc. (Headquarters: Gangnam, Seoul, South Korea; CEO: Junkil Been) in October 2022, and has started selling "Neurophet AQUA" (hereafter, "this product"), an MR device workstation program that uses Deep-Learning, an AI-related technology, to automatically analyze brain region structures from MR images. The exclusive business alliance contract was established through SEOIL E&M Co., Ltd. (Headquarters: Hwaseong City, Gyeonggi Province; CEO: Kunsoo Choi), a specialized trading company for Korean startups.


In Japan, where the aging society is progressing, the increase in the number of dementia patients due to the growing elderly population is becoming a social issue. Early detection of dementia and preventive measures for mild cognitive impairment (MCI), which are pre-dementia, are of great importance.


This product is a medical device program that quantifies and analyzes whole brain MR images using AI technology, calculates and displays brain atrophy and high signal areas in white matter observed in neurodegenerative diseases. It measures 35 locations in a patient's whole brain MR image and analyzes the atrophy patterns of tissues at each site. Based on the results obtained from the analysis, it compares with the standard volumes for each age and gender, and provides an easy-to-understand report on the degree of brain atrophy and high signal areas in white matter.


Clairvo will continue to contribute to solving problems in Japanese healthcare by providing excellent products that support the medical field.